<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="Interrogating the Human Memory B-Cell and Memory-Derived Antibody Repertoire Following" exact="Dengue" post="Virus Infection LyskiZoe L.MesserWilliam B.*[], Department of Molecular Microbiology"/>
 <result pre="B cell immune response against viral pathogens in general and" exact="DENV" post="specifically. Including strengths, limitations, and future directions. Single-cell approaches"/>
 <result pre="limitations, and future directions. Single-cell approaches could help uncover the" exact="DENV" post="specific MBC antibody repertoire, and improved methods for isolating"/>
 <result pre="DENV specific MBC antibody repertoire, and improved methods for isolating" exact="DENV" post="specific monoclonal antibodies from human peripheral blood cells would"/>
 <result pre="viral pathogens, including HIV (11), RSV (12), influenza (13), human" exact="DENV" post="MBC derived antibodies were not fully characterized until 2010"/>
 <result pre="antibodies were not fully characterized until 2010 (14, 15). Mosquito-transmitted" exact="DENV" post="is responsible for ~100 million symptomatic cases and 35,000"/>
 <result pre="it the most common and serious vector-borne disease affecting humans." exact="DENV" post="is an enveloped positive sense RNA virus, that circulates"/>
 <result pre="60–85% shared sequence homology (17). Repeat infections often occur in" exact="DENV" post="endemic regions–Asia, Latin America, Africa, and parts of Oceana."/>
 <result pre="and spread of the vector have led to increasing epidemics." exact="DENV" post="infection causes symptoms that include high fever and rash."/>
 <result pre="vaccines that preferentially elicit potently neutralizing antibodies against all 4" exact="DENV" post="serotypes while avoiding potentially enhancing antibodies. Analyses of human"/>
 <result pre="avoiding potentially enhancing antibodies. Analyses of human antibody response to" exact="DENV" post="infection have traditionally characterized serum antibodies, a product of"/>
 <result pre="(28). Only recently have these methods been employed in the" exact="DENV" post="field. Here we review the leading approaches for characterizing"/>
 <result pre="field. Here we review the leading approaches for characterizing human" exact="DENV" post="MBCs, evaluating their strengths, limitations and potential for further"/>
 <result pre="to EDIII (1M7) or complex (1F4) epitopes on intact virions." exact="DENV" post="specific MBC frequency similar between primary and secondary donors"/>
 <result pre="MBC frequency similar between primary and secondary donors at 14–18" exact="DENV" post="specific MBC per thousand B cells.15 of the isolated"/>
 <result pre="labeled secondary antibodiesIsolated double positive MBCs 20 million PBMCs, 148" exact="DENV" post="E+ MBCs sorted. 1 from an endemic region Serum"/>
 <result pre="from an endemic region Serum neutralized all 4 serotypes 9" exact="DENV" post="E specific MBCs are present in naturally infected donors."/>
 <result pre="are present in naturally infected donors. Authors isolated and characterized" exact="DENV" post="neutralizing mAbs from MBCs against envelope domain I and"/>
 <result pre="culture 64% were positive for IgG, 20% were positive for" exact="DENV" post="by ELISA, 8% secreted DENV2 specific mAbsOf the 9"/>
 <result pre="Appanna et al. (28) FACS using fluorescently labeled DENV3. Isolated" exact="DENV" post="positive MBCs N/A 42° 19 40–60% of the DENV-specific"/>
 <result pre="developed multifunctional FluoroSpot assays allow enumeration of cross-reactive and type-specific" exact="DENV" post="and Zika MBCs following natural infection and vaccination (19,"/>
 <result pre="FluoroSpot assays allow enumeration of cross-reactive and type-specific DENV and" exact="Zika" post="MBCs following natural infection and vaccination (19, 38). This"/>
 <result pre="humans and mice recognize distinct and different epitopes on the" exact="DENV" post="virion following immunization in mice or natural infection in"/>
 <result pre="surface of whole virions (44, 45), in contrast to the" exact="DENV" post="neutralizing antibody response in mice, where the majority of"/>
 <result pre="HIV (47), SARS coronavirus (48), Influenza (49), RSV (50), and" exact="DENV" post="(14, 15, 51). Another technique employed to immortalize MBCs"/>
 <result pre="recognize RSV (52), Hepatitis C virus (54), influenza (55), and" exact="DENV" post="(56). Strengths and Limitations Immortalized B-cells have a plasmablast-like"/>
 <result pre="human immune donors. Recognizing the complex and quaternary nature of" exact="DENV" post="neutralizing epitopes (45) Authors Woda and Mathew (26) and"/>
 <result pre="(26) and Appanna et al. (28) used fluorescently labeled whole" exact="DENV" post="virus (62) as a probe to detect DENV-specific MBCs"/>
 <result pre="in immune donors while Cox et al. (25) used biotinylated" exact="DENV" post="envelope protein as a probe along with dual labeled"/>
 <result pre="a probe along with dual labeled streptavidin antibodies to identify" exact="DENV" post="envelope-specific MBCs. This method enabled researchers to isolate 8"/>
 <result pre="donor (Table 1). Strengths and Limitations Antigen choice is important," exact="DENV" post="neutralizing epitopes are comprised of complex conformational structures and"/>
 <result pre="developed with other pathogens would be expected to advance the" exact="DENV" post="field as well. High-throughput droplet microfluidic approaches (65) allow"/>
 <result pre="(2008) 453:667–71. 10.1038/nature0689018449194 14.BeltramelloMWilliamsKLSimmonsCPMacagnoASimonelliLQuyenNTet al.. The human immune response to" exact="Dengue" post="virus is dominated by highly cross-reactive antibodies endowed with"/>
 <result pre="for dengue vaccine. J Virol. (2018) 92:e00556–18. 10.1128/JVI.00556-1830185598 23.RautRCorbettKSTennekoonRNPremawansaSWijewickramaAPremawansaGet al.." exact="Dengue" post="type 1 viruses circulating in humans are highly infectious"/>
 <result pre="future innovations. Ann Med Surg. (2014) 3:113–6. 10.1016/j.amsu.2014.09.00125568796 43.WahalaWMKrausAAHaymoreLBAccavitti-LoperMAde SilvaAM." exact="Dengue" post="virus neutralization by human immune sera: role of envelope"/>
 <result pre="J Immunol Methods. (2009) 343:65–7. 10.1016/j.jim.2008.11.01219100741 61.WodaMFribergHCurrierJRSrikiatkhachornAMacareoLRGreenSet al.. Dynamics of" exact="Dengue" post="Virus (DENV)-specific B cells in the response to DENV"/>
 <result pre="of Dengue Virus (DENV)-specific B cells in the response to" exact="DENV" post="serotype 1 infections, using flow cytometry with labeled virions."/>
</results>
